> FII flow and rupee will dictate market trend
> Sun Pharmas Ranbaxy acquisition
> Daiichi was unable to run Ranbaxys generic biz
> Ten stocks in focus in Monday morning trade
> Ranbaxy likely to open higher on $3.2 billion deal with Sun Pharma
> Sun Pharma to buy Ranbaxy Laboratories in $3.2 bn deal
> Sun Pharma to acquire Ranbaxy in deal worth $4 bn
> Opening Bell 7 April | Sun Pharma, Ranbaxy in focus on acquisition deal
> Nifty seen opening lower may retest 6650 levels
> Asian Markets, Japan shares slip, others relieved by US data
> Japan shares slip, others relieved by U.S. data
> Flying Blind Monitoring Shadow Banking in Emerging Markets
> Sun Pharmas Ranbaxy acquisition
> Daiichi was unable to run Ranbaxys generic biz
> Ten stocks in focus in Monday morning trade
> Ranbaxy likely to open higher on $3.2 billion deal with Sun Pharma
> Sun Pharma to buy Ranbaxy Laboratories in $3.2 bn deal
> Sun Pharma to acquire Ranbaxy in deal worth $4 bn
> Opening Bell 7 April | Sun Pharma, Ranbaxy in focus on acquisition deal
> Nifty seen opening lower may retest 6650 levels
> Asian Markets, Japan shares slip, others relieved by US data
> Japan shares slip, others relieved by U.S. data
> Flying Blind Monitoring Shadow Banking in Emerging Markets
No comments:
Post a Comment